Pharmacological therapy used in the elimination of Helicobacter pylori infection: A review

World Journal of Gastroenterology

Volumn 21, Issue 1, 2015, Pages 139-154

  Dos Santos, Ariolana A ^a   Carvalho, Adriana A ^a  

^a FEDERAL UNIVERSITY OF SERGIPE   (Brazil)

Author keywords

Clarithromycin resistant; Helicobacter pylori; Peptic ulcers; Treatment; Triple therapy

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ASCORBIC ACID; AZITHROMYCIN; BISMUTH; BISMUTH CITRATE; CLARITHROMYCIN; DOXYCYCLINE; ESOMEPRAZOLE; LAFUTIDINE; LANSOPRAZOLE; LEVOFLOXACIN; METRONIDAZOLE; MOXIFLOXACIN; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; TETRACYCLINE; TINIDAZOLE; ANTIINFECTIVE AGENT;

ABDOMINAL DISCOMFORT; ABDOMINAL DISEASE; ABDOMINAL DISTENSION; ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ANOREXIA; ARTHRALGIA; ARTICLE; BACTERIAL CLEARANCE; BLOATING; CHEILITIS; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG ERUPTION; EPIGASTRIC DISCOMFORT; EPIGASTRIC PAIN; ERADICATION THERAPY; ERUCTATION; FATIGUE; FEVER; FLATULENCE; HALITOSIS; HEADACHE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HICCUP; HUMAN; INSOMNIA; LEG EDEMA; LOOSE FECES; LOSS OF APPETITE; METALLIC TASTE; NAUSEA; PARESTHESIA; PATIENT COMPLIANCE; PRURITUS; RASH; SIDE EFFECT; SORE THROAT; STOMATITIS; SWELLING; TASTE DISORDER; THORAX PAIN; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VAGINA DISCHARGE; VOMITING; ANTIBIOTIC RESISTANCE; DRUG COMBINATION; DRUG EFFECTS; HELICOBACTER INFECTIONS; MICROBIOLOGY; PATHOGENICITY; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PROTON PUMP INHIBITORS; TREATMENT OUTCOME;

EID: 84920869494     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i1.139     Document Type: Article

References (55)

1. Cogo LL, Monteiro CL, Miguel MD, Miguel OG, Cunico MM, Ribeiro ML, de Camargo ER, Kussen GM, Nogueira Kda S, Costa LM. Anti-Helicobacter pylori activity of plant extracts traditionally used for the treatment of gastrointestinal disorders. Braz J Microbiol 2010; 41: 304-309 [PMID: 24031496 DOI: 10.1590/S1517-83822010000200007]
2. Ergül B, Koçak E, Taş A, Filik L, Köklü S. Bismuth, moxifloxacin, tetracycline, lansoprazole quadruple first line therapy for eradication of H. pylori: A prospective study. Clin Res Hepatol Gastroenterol 2013; 37 : 527-529 [PMID: 23312494 DOI: 10.1016/j.clinre.2012.10.014]
3. Bytzer P, Dahlerup JF, Eriksen JR, Jarbøl DE, Rosenstock S, Wildt S. Diagnosis and treatment of Helicobacter pylori infection. Dan Med Bull 2011; 58: C4271 [PMID: 21466771]
4. Tytgat GN . Etiopathogenetic principles and peptic ulcer disease classification. Dig Dis 2011; 29 : 454-458 [PMID: 22095009 DOI: 10.1159/000331520]
5. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102 : 1808-1825 [PMID: 17608775 DOI: 10.1111/j.1572-0241.2007.01393.x]
6. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56: 772-781 [PMID: 17170018 DOI: 10.1136/gut.2006.101634]
7. Fock KM, Katelaris P, Sugano K, Ang TL, Hunt R, Talley NJ, Lam SK, Xiao SD, Tan HJ, Wu CY, Jung HC, Hoang BH, Kachintorn U, Goh KL, Chiba T, Rani AA. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 2009; 24: 1587-1600 [PMID: 19788600 DOI: 10.1111/j.1440-1746.2009.05982.x]
8. Chung JW, Lee GH, Han JH, Jeong JY, Choi KS, Kim do H, Jung KW, Choi KD, Song HJ, Jung HY, Kim JH. The trends of one-week first-line and second-line eradication therapy for Helicobacter pylori infection in Korea. Hepatogastroenterology 2011; 58: 246-250 [PMID: 21510323]
9. Coelho LG, Maguinilk I, Zaterka S, Parente JM, do Carmo Friche Passos M, Moraes-Filho JP. 3rd Brazilian Consensus on Helicobacter pylori. Arq Gastroenterol 2013; 50: S0004-28032013005000113 [PMID: 23748591]
10. Jodlowski TZ, Lam S, Ashby CR. Emerging therapies for the treatment of Helicobacter pylori infections. Ann Pharmacother 2008; 42: 1621-1639 [PMID: 18845620 DOI: 10.1345/aph.1L234]
11. Dib J Jr, Alvarez B, Mendez L, Cruz ME. Efficacy of PPI, levofloxacin and amoxicillin in the eradication of Helicobacter pylori compared to conventional triple therapy at a Venezuelan hospital. Arab J Gastroenterol 2013; 14 : 123-125 [PMID: 24206741 DOI: 10.1016/j.ajg.2013.09.001]
12. Wolle K, Malfertheiner P. Treatment of Helicobacter pylori. Best Pract Res Clin Gastroenterol 2007; 21: 315-324 [PMID: 17382279 DOI: 10.1016/j.bpg.2006.11.001]
13. Tanih NF, Dube C, Green E, Mkwetshana N, Clarke AM, Ndip LM, Ndip RN. An African perspective on Helicobacter pylori: prevalence of human infection, drug resistance, and alternative approaches to treatment. Ann Trop Med Parasitol 2009; 103: 189-204 [PMID: 19341534 DOI: 10.1179/136485909X398311]
14. Zullo A, De Francesco V, Scaccianoce G, Manes G, Efrati C, Hassan C, Maconi G, Piglionica D, Cannaviello C, Panella C, Morini S, Ierardi E. Helicobacter pylori eradication with either quadruple regimen with lactoferrin or levofloxacin-based triple therapy: a multicentre study. Dig Liver Dis 2007; 39: 806-810 [PMID: 17644057]
15. Sokwala A, Shah MV, Devani S, Yonga G. Helicobacter pylori eradication: A randomised comparative trial of 7-day versus 14-day triple therapy. S Afr Med J 2012; 102: 368-371 [PMID: 22668909]
16. Onyekwere CA, Odiagah JN, Igetei R, Emanuel AO, Ekere F, Smith S. Rabeprazole, clarithromycin, and amoxicillin Helicobacter pylori eradication therapy: report of an efficacy study. World J Gastroenterol 2014; 20 : 3615-3619 [PMID: 24707145 DOI: 10.3748/wjg.v20.i13.3615]
17. Kudo T, Fujinami H, Ando T, Nishikawa J, Ogawa K, Hosokawa A, Orihara T, Murakami J, Takahara T, Sugiyama T. Comparison of lafutidine and rabeprazole in 7-day second-line amoxicillin- and metronidazole-containing triple therapy for Helicobacter pylori: a pilot study. Helicobacter 2012; 17: 277-281 [PMID: 22759327 DOI: 10.1111/j.1523-5378.2012.00943.x]
18. Bago J, Majstorović K, Belosić-Halle Z, Kućisec N, Bakula V, Tomić M, Bago P, Troskot R. Antimicrobial resistance of H. pylori to the outcome of 10-days vs. 7-days Moxifloxacin based therapy for the eradication: a randomized controlled trial. Ann Clin Microbiol Antimicrob 2010; 9 : 13 [PMID: 20398300 DOI: 10.1186/1476-0711-9-13]
19. Dong J, Yu XF, Zou J. Azithromycin-containing versus standard triple therapy for Helicobacter pylori eradication: a meta-analysis. World J Gastroenterol 2009; 15 : 6102-6110 [PMID: 20027685 DOI: 10.3748/wjg.15.6102]
20. Li G, Li L, Yu C, Chen L. Effect of vitamins C and E supplementation on Helicobacter pylori eradication: a meta-analysis. Br J Nutr 2011; 106 : 1632-1637 [PMID: 21810287 DOI: 10.1017/S0007114511003813]
21. Güzelbulut F, Sezikli M, Akkan Çetinkaya Z, Erhan Altunöz M, Günes P, Düzgün S, Ovünç Kurdas O. Application of levofloxacine in the second phase of sequential therapy regimen for Helicobacter pylori eradication: is it a good choice? Minerva Med 2011; 102: 171-176 [PMID: 21593719]
22. Chen LW, Chien RN, Chang JJ, Fang KM, Chang LC. Comparison of the once-daily levofloxacin-containing triple therapy with the twice-daily standard triple therapy for first-line Helicobacter pylori eradication: a prospective randomised study. Int J Clin Pract 2010; 64: 1530-1534 [PMID: 20846200 DOI: 10.1111/j.1742-1241.2010.02482.x]
23. Zheng Q, Chen WJ, Lu H, Sun QJ, Xiao SD. Comparison of the efficacy of triple versus quadruple therapy on the eradication of Helicobacter pylori and antibiotic resistance. J Dig Dis 2010; 11: 313-318 [PMID: 20883428 DOI: 10.1111/ j.1751-2980.2010.00457.x]
24. Seven G, Cinar K, Yakut M, Id?lman R, Ozden A. Assessment of Helicobacter pylori eradication rate of triple combination therapy containing levofloxacin. Turk J Gastroenterol 2011; 22: 582-586 [PMID: 22287402]
25. Assem M, El Azab G, Rasheed MA, Abdelfatah M, Shastery M. Efficacy and safety of Levofloxacin, Clarithromycin and Esomeprazol as first line triple therapy for Helicobacter pylori eradication in Middle East. Prospective, randomized, blind, comparative, multicenter study. Eur J Intern Med 2010; 21: 310-314 [PMID: 20603042 DOI: 10.1016/j.ejim.2010.05.011]
26. Chen MC, Lei WY, Lin JS, Yi CH, Wu DC, Hu CT. Levofloxacin-amoxicillin/clavulanate-rabeprazole versus a standard seven-day triple therapy for eradication of Helicobacter pylori infection. Biomed Res Int 2014; 2014 : 158520 [PMID: 24995271 DOI: 10.1155/2014/158520]
27. Nishida T, Tsujii M, Tanimura H, Tsutsui S, Tsuji S, Takeda A, Inoue A, Fukui H, Yoshio T, Kishida O, Ogawa H, Oshita M, Kobayashi I, Zushi S, Ichiba M, Uenoyama N, Yasunaga Y, Ishihara R, Yura M, Komori M, Egawa S, Iijima H, Takehara T. Comparative study of esomeprazole and lansoprazole in triple therapy for eradication of Helicobacter pylori in Japan. World J Gastroenterol 2014; 20: 4362-4369 [PMID: 24764674 DOI: 10.3748/wjg.v20.i15.4362]
28. Vakil N. Antimicrobial resistance and eradication strategies for Helicobacter pylori. Rev Gastroenterol Disord 2009; 9: E78-E83 [PMID: 19898268]
29. Vilaichone RK, Gamnarai P, Mahachai V. M1072 Changing Pattern of Antibiotic Resistant Strains of Helicobacter pylori Infection in Thailand. Gastroenterol 2009; 19: 5508-5512 [DOI: 10.1016/S0016-5085(09)61575-4]
30. Federico A, Nardone G, Gravina AG, Iovene MR, Miranda A, Compare D, Pilloni PA, Rocco A, Ricciardiello L, Marmo R, Loguercio C, Romano M. Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection. Gastroenterology 2012; 143: 55-61.e1; quize e13-14 [PMID: 22484118 DOI: 10.1053/j.gastro.2012.03.043]
31. Francavilla R, Lionetti E, Magistà A, Castellaneta S, De Canio A, Bucci N, Piscitelli D, Cavallo L, Ierardi E. Clinical impact of Helicobacter pylori clarithromycin resistance on eradicating therapies in children: A cohort retrospective study. Digestive and Liver Disease 2008; 40 : A91 [DOI: 10.1016/j.dld.2008.07.262]
32. Kaboli SA, Zojaji H, Mirsattari D, Talaie R, Derakhshan F, Zali MR, Sheikhvatan M. Effect of addition of vitamin C to clarithromycin-amoxicillin-omeprazol triple regimen on Helicobacter pylori eradication. Acta Gastroenterol Belg 2009; 72: 222-224 [PMID: 19637777]
33. Zojaji H, Talaie R, Mirsattari D, Haghazali M, Molaei M, Mohsenian N, Derakhshan F, Zali MR. The efficacy of Helicobacter pylori eradication regimen with and without vitamin C supplementation. Dig Liver Dis 2009; 41: 644-647 [PMID: 19493713 DOI: 10.1016/j.dld.2008.09.008]
34. Lins AK, Lima RA, Magalhães M. Clarithromycin-resistant Helicobacter pylori in Recife, Brazil, directly identified from gastric biopsies by polymerase chain reaction. Arq Gastroenterol 2010; 47: 379-382 [PMID: 21225149 DOI: 10.1590/S0004-28032010000400011]
35. Trespalacios AA, Otero RW, Mercado RM. Resistencia de Helicobacter pylori a metronidazol, claritromicina y amoxicilina en pacientes colombianos. Rev Col Gastroenterol 2010; 25: 31-38
36. Kaya AD, Oztürk CE, Akcan Y, Behçet M, Karakoç AE, Yücel M, Misirlioglu M, Tuncer S. Prevalence of Helicobacter pylori in symptomatic patients and detection of clarithromycin resistance using melting curve analysis. Curr Ther Res Clin Exp 2007; 68: 151-160 [PMID: 24683206 DOI: 10.1016/j.curtheres.2007.06.001]
37. Liou JM, Chen CC, Chen MJ, Chen CC, Chang CY, Fang YJ, Lee JY, Hsu SJ, Luo JC, Chang WH, Hsu YC, Tseng CH, Tseng PH, Wang HP, Yang UC, Shun CT, Lin JT, Lee YC, Wu MS. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet 2013; 381: 205-213 [PMID: 23158886 DOI: 10.1016/S0140-6736(12)61579-7]
38. Polat Z, Kadayifci A, Kantarcioglu M, Ozcan A, Emer O, Uygun A. Comparison of levofloxacin-containing sequential and standard triple therapies for the eradication of Helicobacter pylori. Eur J Intern Med 2012; 23: 165-168 [PMID: 22284248 DOI: 10.1016/j.ejim.2011.02.011]
39. Cetinkaya ZA, Sezikli M, Güzelbulut F, Coşgun S, Düzgün S, Kurdaş OO. Comparison of the efficacy of the two tetracycline-containing sequential therapy regimens for the eradication of Helicobacter pylori: 5 days versus 14 days amoxicillin. Helicobacter 2010; 15: 143-147 [PMID: 20402816 DOI: 10.1111/j.1523-5378.2010.00747.x]
40. Karatapanis S, Georgopoulos SD, Papastergiou V, Skorda L, Papantoniou N, Lisgos P, Kouvidou C, Fragkou P, Mentis A. "7, 10 and 14-days rabeprazole-based standard triple therapies for H. pylori eradication: are they still effective? A randomized trial". Acta Gastroenterol Belg 2011; 74: 407-412 [PMID: 22103045]
41. Uygun A, Ozel AM, Sivri B, Polat Z, Genç H, Sakin YS, Çelebi G, Uygur-Bayramiçli O, Erçin CN, Kadayifçi A, Emer O, Gunal A, Bagci S. Efficacy of a modified sequential therapy including bismuth subcitrate as first-line therapy to eradicate Helicobacter pylori in a Turkish population. Helicobacter 2012; 17: 486-490 [PMID: 23067136 DOI: 10.1111/ j.1523-5378.2012.00989.x]
42. Tursi A, Picchio M, Elisei W. Efficacy and tolerability of a third-line, levofloxacin-based, 10-day sequential therapy in curing resistant Helicobacter pylori infection. J Gastrointestin Liver Dis 2012; 21: 133-138 [PMID: 22720300]
43. Choi HS, Chun HJ, Park SH, Keum B, Seo YS, Kim YS, Jeen YT, Um SH, Lee HS, Kim CD, Ryu HS. Comparison of sequential and 7-, 10-, 14-d triple therapy for Helicobacter pylori infection. World J Gastroenterol 2012; 18 : 2377-2382 [PMID: 22654429 DOI: 10.3748/wjg.v18.i19.2377]
44. Sasaki M, Ogasawara N, Utsumi K, Kawamura N, Kamiya T, Kataoka H, Tanida S, Mizoshita T, Kasugai K, Joh T. Changes in 12-Year First-Line Eradication Rate of Helicobacter pylori Based on Triple Therapy with Proton Pump Inhibitor, Amoxicillin and Clarithromycin. J Clin Biochem Nutr 2010; 47: 53-58 [PMID: 20664731 DOI: 10.3164/jcbn.10-10]
45. Bang SY, Han DS, Eun CS, Kim JE, Ahn SB, Sohn JH, Jeon YC, Kang JO. [Changing patterns of antibiotic resistance of Helicobacter pylori in patients with peptic ulcer disease]. Korean J Gastroenterol 2007; 50: 356-362 [PMID: 18159172]
46. Seyedmajidi S, Mirsattari D, Zojaji H, Zanganeh E, Seyyedmajidi M, Almasi S, Zali M. Penbactam for Helicobacter pylori eradication: a randomised comparison of quadruple and triple treatment schedules in an Iranian population. Arab J Gastroenterol 2013; 14: 1-5 [PMID: 23622801 DOI: 10.1016/j.ajg.2012.12.004]
47. Seyedmajidi S, Mirsattari D, Zojaji H, Zanganeh E, Seyyedmajidi M, Almasi S, Zali M. Penbactam for Helicobacter pylori eradication: a randomised comparison of quadruple and triple treatment schedules in an Iranian population. Arab J Gastroenterol 2013; 14: 1-5 [PMID: 23622801 DOI: 10.1016/j.ajg.2010.09.001]
48. Xu MH, Zhang GY, Li CJ. [Efficacy of bismuth-based quadruple therapy as first-line treatment for Helicobacter pylori infection]. Zhejiang Da Xue Xue Bao Yi Xue Ban 2011; 40: 327-331 [PMID: 21671496]
49. Wang Z, Wu S. Doxycycline-based quadruple regimen versus routine quadruple regimen for rescue eradication of Helicobacter pylori: an open-label control study in Chinese patients. Singapore Med J 2012; 53: 273-276 [PMID: 22511052]
50. Bismuth + metronidazole + tetracycline. Why risk adding bismuth? Prescrire Int 2013; 22: 89-92 [PMID: 23662315]
51. Lee BH, Kim N, Hwang TJ, Lee SH, Park YS, Hwang JH, Kim JW, Jeong SH, Lee DH, Jung HC, Song IS. Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea. Helicobacter 2010; 15: 38-45 [PMID: 20302588 DOI: 10.1111/j.1523-5378.2009.00735.x]
52. Agah S, Shazad B, Abbaszadeh B. Comparison of azithromycin and metronidazole in a quadruple-therapy regimen for Helicobacter pylori eradication in dyspepsia. Saudi J Gastroenterol 2009; 15: 225-228 [PMID: 19794266 DOI: 10.4103/1319-3767.56091]
53. Rogha M, Pourmoghaddas Z, Rezaee M, Shirneshan K, Shahi Z. Azithromycin effect on helicobacter pylori eradication: double blind randomized clinical trial. Hepatogastroenterology 2009; 56: 722-724 [PMID: 19621690]
54. Hsu PI, Wu DC, Chen WC, Tseng HH, Yu HC, Wang HM, Kao SS, Lai KH, Chen A, Tsay FW. Randomized controlled trial comparing 7-day triple, 10-day sequential, and 7-day concomitant therapies for Helicobacter pylori infection. Antimicrob Agents Chemother 2014; 58 : 5936-5942 [PMID: 25070099 DOI: 10.1128/AAC.02922-14]
55. Liu KS, Hung IF, Seto WK, Tong T, Hsu AS, Lam FY, But DY, Wong SY, Leung WK. Ten day sequential versus 10 day modified bismuth quadruple therapy as empirical firstline and secondline treatment for Helicobacter pylori in Chinese patients: an open label, randomised, crossover trial. Gut 2014; 63: 1410-1415 [PMID: 24295850 DOI: 10.1136/gutjnl-2013-30612]